Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 7/20 | 0.59 |
| ▸ | ACE | P12821 | 6/20 | 0.59 |
| ▸ | CPA1 | P15085 | 2/20 | 0.59 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.59 |
| ▸ | CA2 | P00918 | 1/20 | 0.55 |
| ▸ | ALB | P02768 | 1/20 | 0.53 |
| ▸ | IL2 | P60568 | 1/20 | 0.53 |
| ▸ | PIN1 | Q13526 | 2/20 | 0.52 |
| ▸ | MMP9 | P14780 | 2/20 | 0.50 |
| ▸ | MMP8 | P22894 | 2/20 | 0.50 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.47 |
| ▸ | CDC25B | P30305 | 1/20 | 0.47 |
| ▸ | CTSL | P07711 | 1/20 | 0.47 |
| ▸ | CTSB | P07858 | 1/20 | 0.47 |
| ▸ | CTSS | P25774 | 1/20 | 0.47 |
| ▸ | CTSK | P43235 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL805215 | 0.84 | MME (0.61) | MMEACECPA1ACE2CA2 | |
| SCHEMBL29377272 | 0.84 | MME (0.59) | MMEACECPA1ACE2CA2 | |
| SCHEMBL29981964 | 0.84 | MME (0.61) | MMEACECPA1ACE2CA2 | |
| SCHEMBL8895051 | 0.84 | MME (0.61) | MMEACECPA1ACE2CA2 | |
| SCHEMBL18435353 | 0.84 | MME (0.59) | MMEACECPA1ACE2CA2 | |
| SCHEMBL24625336 | 0.84 | MME (0.59) | MMEACECPA1ACE2CA2 | |
| SCHEMBL30498632 | 0.84 | MME (0.61) | MMEACECPA1ACE2CA2 | |
| SCHEMBL10071066 | 0.84 | MME (0.61) | MMEACECPA1ACE2CA2 | |
| SCHEMBL31022161 | 0.83 | MME (0.57) | MMEACECPA1ACE2CA2 | |
| SCHEMBL22764712 | 0.83 | MME (0.64) | MMEACECPA1ACE2CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025072246-A9 | COMPOUNDS AND METHODS FOR SKIPPING EXON 50 IN DUCHENNE MUSCULAR DYSTROPHY | ENTRADA THERAPEUTICS, INC. (US) | 2025-05-08 | — | — | WO | claimed |
| WO-2025072246-A1 | COMPOUNDS AND METHODS FOR SKIPPING EXON 50 IN DUCHENNE MUSCULAR DYSTROPHY | ENTRADA THERAPEUTICS, INC. (US) | 2025-04-03 | — | — | WO | claimed |
| US-20260146063-A1 | CYCLIC CELL PENETRATING PEPTIDES AND METHODS OF MAKING AND USING THEREOF | OHIO STATE INNOVATION FOUNDATION (US) | 2026-05-28 | — | — | US | disclosed |
| US-20260070947-A1 | CYCLIC CELL-PENETRATING PEPTIDE COMPOUNDS | OHIO STATE INNOVATION FOUNDATION (US) | 2026-03-12 | — | — | US | disclosed |
| US-20260070948-A1 | CYCLIC CELL-PENETRATING PEPTIDES WITH CARGO | OHIO STATE INNOVATION FOUNDATION (US) | 2026-03-12 | — | — | US | disclosed |
| US-20260008813-A1 | CELL-PENETRATING PEPTIDE COMPOUNDS | OHIO STATE INNOVATION FOUNDATION (US) | 2026-01-08 | — | — | US | disclosed |
| US-20260008812-A1 | CELL-PENETRATING PEPTIDE COMPOUNDS | OHIO STATE INNOVATION FOUNDATION (US) | 2026-01-08 | — | — | US | disclosed |
| US-20260008816-A1 | CYCLIC CELL PENETRATING PEPTIDES AND METHODS OF MAKING AND USING THEREOF | OHIO STATE INNOVATION FOUNDATION (US) | 2026-01-08 | — | — | US | disclosed |
| US-20260001916-A1 | CYCLIC CELL-PENETRATING PEPTIDE COMPOUNDS | OHIO STATE INNOVATION FOUNDATION (US) | 2026-01-01 | — | — | US | disclosed |
| US-12454552-B2 | Cyclic cell penetrating peptides comprising beta-hairpin motifs and methods of making and using thereof | OHIO STATE INNOVATION FOUNDATION (US) | 2025-10-28 | — | — | US | disclosed |
| WO-2025072246-A9 | COMPOUNDS AND METHODS FOR SKIPPING EXON 50 IN DUCHENNE MUSCULAR DYSTROPHY | ENTRADA THERAPEUTICS, INC. (US) | 2025-05-08 | — | — | WO | disclosed |
| US-20240368227-A1 | CYCLIC CELL-PENETRATING PEPTIDES WITH ONE OR MORE HYDROPHOBIC RESIDUES | OHIO STATE INNOVATION FOUNDATION | 2024-11-07 | — | — | US | disclosed |
| US-20240360174-A1 | CELL-PENETRATING PEPTIDE SEQUENCES | OHIO STATE INNOVATION FOUNDATION | 2024-10-31 | — | — | US | disclosed |
| US-11987647-B2 | Cyclic cell-penetrating peptides with one or more hydrophobic residues | OHIO STATE INNOVATION FOUNDATION (US) | 2024-05-21 | — | — | US | disclosed |
| US-20240158445-A1 | CYCLIC CELL-PENETRATING PEPTIDES WITH THREE OR MORE HYDROPHOBIC RESIDUES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-05-16 | — | — | US | disclosed |
| EP-4294820-A1 | CYCLIC CELL-PENETRATING PEPTIDES WITH THREE OR MORE HYDROPHOBIC RESIDUES | Ohio State Innovation Foundation (US) | 2023-12-27 | — | — | EP | disclosed |
| US-20220306693-A1 | CYCLIC CELL PENETRATING PEPTIDES COMPRISING BETA-HAIRPIN MOTIFS AND METHODS OF MAKING AND USING THEREOF | OHIO STATE INNOVATION FOUNDATION | 2022-09-29 | — | — | US | disclosed |
| WO-2022178379-A1 | CYCLIC CELL-PENETRATING PEPTIDES WITH THREE OR MORE HYDROPHOBIC RESIDUES | OHIO STATE INNOVATION FOUNDATION (US) | 2022-08-25 | — | — | WO | disclosed |
| US-20220177523-A1 | CELL PENETRATING PEPTIDES AND METHODS OF MAKING AND USING THEREOF | ENTRADA THERAPEUTICS, INC. | 2022-06-09 | — | — | US | disclosed |
| US-11352394-B2 | Cyclic cell penetrating peptides comprising beta-hairpin motifs and methods of making and using thereof | OHIO STATE INNOVATION FOUNDATION (US) | 2022-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11352394-B2 | Cyclic cell penetrating peptides comprising beta-hairpin motifs and methods of making and using thereof | VIP, LNPEP, IAPP | MME 417/4885ACE 3502/4885CPA1 123/4885 |
| US-20240368227-A1 | CYCLIC CELL-PENETRATING PEPTIDES WITH ONE OR MORE HYDROPHOBIC RESIDUES | VIP, LNPEP, TAP1 | MME 649/4885ACE 4059/4885CPA1 180/4885 |
| US-20260008816-A1 | CYCLIC CELL PENETRATING PEPTIDES AND METHODS OF MAKING AND USING THEREOF | SLC3A2, SPPL2B, SLC7A1 | MME 2100/4885ACE 3419/4885CPA1 590/4885 |
| US-20260008812-A1 | CELL-PENETRATING PEPTIDE COMPOUNDS | SLC38A7, SLC7A1, SLC6A7 | MME 700/4885ACE 1939/4885CPA1 88/4885 |
| US-20260146063-A1 | CYCLIC CELL PENETRATING PEPTIDES AND METHODS OF MAKING AND USING THEREOF | VIP, SLC7A1, SLC6A15 | MME 753/4885ACE 1946/4885CPA1 172/4885 |
| US-20220306693-A1 | CYCLIC CELL PENETRATING PEPTIDES COMPRISING BETA-HAIRPIN MOTIFS AND METHODS OF MAKING AND USING THEREOF | CHN2, TAP2, VIP | MME 1642/4885ACE 3325/4885CPA1 247/4885 |
| US-20220177523-A1 | CELL PENETRATING PEPTIDES AND METHODS OF MAKING AND USING THEREOF | VIP, LNPEP, TAP1 | MME 286/4885ACE 3899/4885CPA1 199/4885 |
| US-20260070947-A1 | CYCLIC CELL-PENETRATING PEPTIDE COMPOUNDS | SLC7A1, SLC38A7, SLC6A19 | MME 1634/4885ACE 2843/4885CPA1 215/4885 |
| US-20260070948-A1 | CYCLIC CELL-PENETRATING PEPTIDES WITH CARGO | SLC7A1, SLC38A7, SLC6A19 | MME 1262/4885ACE 2988/4885CPA1 139/4885 |
| US-20260001916-A1 | CYCLIC CELL-PENETRATING PEPTIDE COMPOUNDS | SLC7A1, SLC38A7, SLC6A19 | MME 630/4885ACE 2236/4885CPA1 169/4885 |
| US-12454552-B2 | Cyclic cell penetrating peptides comprising beta-hairpin motifs and methods of making and using thereof | CHN2, TAP2, VIP | MME 1642/4885ACE 3325/4885CPA1 247/4885 |
| US-20260008813-A1 | CELL-PENETRATING PEPTIDE COMPOUNDS | SLC7A1, SLC38A7, SLC6A19 | MME 933/4885ACE 2506/4885CPA1 64/4885 |
| US-20240158445-A1 | CYCLIC CELL-PENETRATING PEPTIDES WITH THREE OR MORE HYDROPHOBIC RESIDUES | SLC3A2, SLC7A1, ARGLU1 | MME 1508/4885ACE 4661/4885CPA1 367/4885 |
| US-20240360174-A1 | CELL-PENETRATING PEPTIDE SEQUENCES | VIP, LNPEP, NGLY1 | MME 397/4885ACE 3539/4885CPA1 56/4885 |
| US-11987647-B2 | Cyclic cell-penetrating peptides with one or more hydrophobic residues | VIP, LNPEP, TAP1 | MME 649/4885ACE 4059/4885CPA1 180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.